Xenon Pharmaceuticals stock plunges on mixed FDA filing and psychiatry safety news

Xenon Pharmaceuticals shares dropped 25.2% in after-hours trading following a two-part announcement that combined a much-anticipated regulatory step with a concerning safety update from its psychiatric drug program. The company filed a New Drug Application with the U.S. Food and Drug Administration for azetukalner in focal seizures associated with epilepsy, and at the same time disclosed a voluntary halt to new patient enrollment in its ongoing Phase 3 studies for major depressive disorder and bipolar depression.

The decision to pause enrollment followed a review of neuropsychiatric adverse events reported in the psychiatry studies. Xenon said those events were consistent with azetukalner's known mechanism of action, but they had not appeared in the earlier Phase 2 X-NOVA trial in MDD. According to the company, the pause was a precautionary measure taken after consultation with its Data Safety Monitoring Board, and participants already enrolled in the psychiatry trials would continue to take part.

The selloff underscores how much Xenon's valuation depends on its psychiatry pipeline. Before today, several Wall Street analysts had kept bullish ratings on the shares, and the epilepsy NDA submission had been widely expected after strong Phase 3 X-TOLE2 results. The unforeseen safety signal in the psychiatry program created significant uncertainty around Phase 3 X-NOVA2 topline data, which had been anticipated in the first half of 2027. At the same time, the wider U.S. stock market provided no clear direction, as the S&P 500 and Nasdaq finished the session roughly flat.

For investors, the landmark NDA filing and the jarring clinical safety pause produced a sharply mixed picture, and the safety news clearly drove sentiment. With the stock at $42.90, it is now closer to the bottom of its 52-week range of $35.97-$72.66, wiping out months of gains that had been built on hopes for azetukalner across multiple indications.

AI tools supported the creation of this article, which was subsequently reviewed by an editor. See our T&C for more information.